

May 29, 2026

To
**Department of Corporate Affairs- Listing
BSE Limited**
PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]
ISIN: INE285U01025

Sub: Outcome of Board Meeting held on May 29, 2026 (Friday)

Dear Sir,

Pursuant to Regulation 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have enclosed herewith:

1. Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026, including the Statement of Assets and Liabilities and Statement of Cash Flows, duly approved and taken on record by the Board of Directors at their meeting held today i.e. Friday, May 29, 2026; &
2. Independent Auditor's Report (Standalone) on the aforesaid results, as placed before the Board of Directors of the Company at its meeting held today.

The Board Meeting commenced at 03:55 p.m. and concluded at 4.35 p.m. The

Kindly take the above information on your records.

Thanking You,
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**

ABHISHEK
KUMAR PANDEY

Digitally signed by ABHISHEK KUMAR
PANDEY
DN: cn=ABHISHEK KUMAR PANDEY c=IN
o=Personal
Reason: I am the author of this document
Location:
Date: 2026-05-29 16:51+05:30

**ABHISHEK K. PANDEY
COMPANY SECRETARY
M.NO F12457
PLACE: GURGAON
Encl.: a/a**

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsji, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel.: +91 11 47063600, 470630601



INDEPENDENT AUDITOR'S REPORT

To,
The Members of,
Kimia Biosciences Limited

Report on the Audit of Financial Statements

Opinion

We have audited the accompanying Ind AS financial statements of **Kimia Biosciences Limited**, ("the Company"), which comprise the Balance Sheet as at 31st March 2026, the Statement of Profit & Loss, (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended 31st March 2026, and notes to the Ind AS Financial Statements, including a summary of material accounting policies information and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Companies Act, 2013 as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, its profit including other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing (SAs), specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Ind AS Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Ind AS financial statements for the financial year ended March 31, 2026. These matters were addressed in the context of our audit of the Ind AS financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each key audit matter below, our description of how our audit addressed the matter is provided in that context.

We have determined the matters described below to be the key audit matters to be communicated in our report. We have fulfilled the responsibilities described in the 'Auditor's responsibilities for the audit of the Ind AS financial statements' section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the Ind AS financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying Ind AS financial statements.



Key Audit Matters	How our audit addressed the Key Audit Matters
<p>Revenue Recognition - The management is of the opinion that it controls the goods before transferring them to the customer. The variety of terms that define when control is transferred to the customer, as well as the high value of the transactions, give rise to the risk that revenue is not recognized in the appropriate accounting period.</p> <p>Revenue is measured net of returns and allowances, trade discounts and volume rebates (collectively 'Discount and rebates'). There is a risk that these discount and rebates are incorrectly recorded as it also requires ascertain degree of estimation, resulting in understatement of the associated expenses and accrual.</p> <p>Accordingly, due to the significant risk associated with revenue recognition in accordance with terms of Ind AS 115</p> <p>'Revenue from Contracts with Customers', it was determined to be a key audit matter in our audit of the Ind AS Financial Statements.</p>	<p>We assessed the Company's process to identify the impact of adoption of new Revenue Accounting Standard (Ind AS 115). Our audit approach included assessment of design and testing of operating effectiveness of internal controls related to revenue recognition, calculation of discounts and rebates and other substantive testing. We carried out:</p> <p>Evaluation of the design of internal controls relating to implementation of new revenue accounting standard.</p> <ul style="list-style-type: none"> • Selection of samples of both continuing and new contracts for <ul style="list-style-type: none"> - testing of operating effectiveness of the internal control - identification of contract wise performance obligations and - Determination of transaction price. • Verification of individual sales transaction on sample basis and traced to sales invoices, sales orders and other related documents. Further, the samples were checked for revenue recognition as per the shipping terms. • Sample of sales transactions were selected pre- and post-year end, agreeing the period of revenue recognition to third party support, such as transporter invoice and customer confirmation of receipt of goods. • Direct confirmations were obtained from customers to support existence assertion of trade receivables and assessed the relevant disclosures made in the Financial Statements. to ensure revenue from contracts with customers are in accordance with the requirements of relevant accounting standards. • In the cases where direct confirmations are not available, additional procedures were applied in respect of receipts in the Subsequent period.



Key Audit Matters	How our audit addressed the Key Audit Matters
<ul style="list-style-type: none"> • The Company incurs significant expenditure on Research and Development (“R&D”) activities, which is critical to its pharmaceutical product development and manufacturing processes, including development of new products/processes and improvement of existing formulations. • Revenue expenditure on R&D activities is generally charged to the Statement of Profit and Loss in the period in which it is incurred under the head “Research and Development Expenses”. Expenditure incurred on acquisition of equipment and facilities used for R&D activities is capitalized as Property, Plant and Equipment and depreciated over its estimated useful life in accordance with the Company’s accounting policies. • During the current reporting period, the Company has reassessed its accounting treatment for certain R&D-related expenditures to ensure compliance with Ind AS 38 – Intangible Assets. Based on this reassessment, certain costs which were previously expensed in earlier periods have been evaluated for recognition as intangible assets, where such expenditure meets the recognition criteria prescribed under the standard, including technical feasibility of development, intention to complete, and availability of future economic benefits. • This area involves significant management judgement in determining classification of expenditure, assessment of technical feasibility of product/process development, and evaluation of future economic benefits and recoverability. Accordingly, the accounting for R&D expenditure has been identified as a Key Audit Matter due to the degree of estimation uncertainty and judgement involved, as well as its significance to the financial statements. 	<p>Our audit procedures included, among others:</p> <ul style="list-style-type: none"> • Understanding and evaluating the Company’s process for identification, classification, and accounting of R&D expenditure, including design and implementation of relevant internal controls. • Examining the Company’s accounting policies relating to R&D expenditure and assessing their compliance with the requirements of Ind AS 38 – Intangible Assets. • Testing on a sample basis, supporting documentation for R&D expenditure incurred during the year to determine whether such costs are appropriately classified as revenue or capital in nature. • Evaluating management’s assessment of technical feasibility, intention to complete development, availability of resources, and expected future economic benefits for costs capitalized as intangible assets. • Assessing the reasonableness of key judgments and estimates applied by management, including consideration of historical success rates of R&D projects where relevant. • Reviewing disclosures made in the financial statements in respect of R&D expenditure and changes in accounting treatment for adequacy and compliance with applicable accounting standards. <p>Based on the procedures performed, we found management’s assessment and accounting treatment of R&D expenditure to be reasonable and disclosures to be adequate in accordance with applicable accounting standards.</p>

We have determined that there are no other key audit matters to communicate in our report.



Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report 2025-26, but does not include the Ind AS financial statements and our auditor's report thereon.

Our opinion on the Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Ind AS financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Ind AS financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

The Company has established a state-of-the-art Research & Development (R&D) facility at its registered office premises, located in a separate building/unit at Village Bhondsi, Tehsil Sohna, District Gurugram, Haryana. The facility is primarily engaged in the development of new products and processes, improvement of existing products and processes for cost optimization, and development of new Active Pharmaceutical Ingredients (APIs).

The aforesaid R&D facility has been duly recognized and approved by the Department of Scientific and Industrial Research (DSIR) vide Registration No. TU/IV-RD/4410/2018 dated January 22, 2019.

Based on our audit procedures performed and according to the information and explanations given to us, we are of the opinion that the Company has maintained separate books of account in respect of the aforesaid R&D facility. Further, proper records, as prescribed under the applicable provisions of the Income-tax Rules, 1962 and the guidelines issued by DSIR, have been maintained in all material respects.

Responsibilities of Management and Those charged with Governance for the Ind AS Financials Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Ind AS financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian accounting Standards (Ind AS) specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities. selection and application of appropriate accounting policies. making judgments and estimates that are reasonable and prudent. and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the Ind AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding among other matters, the planned scope and timing of the audit and significant audit findings, including any significant internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - (c) The Balance Sheet, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Companies (Ind AS) Rules, 2015, as amended.
 - (e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**".
 - (g) In our opinion, the managerial remuneration for the year ended March 31, 2026 has been paid/ provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Companies Act, 2013.
 - (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - ❖ The Company has disclosed the impact of pending litigations on its financial position in its financial statements-Refer Note 37 to the financial statements.
 - ❖ The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - ❖ There was no amount which required to be transferred to the Investor Education and Protection Fund



by the Company.

- ❖ (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any persons or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

- ❖ The Company has not paid any dividend during the year ended March 31, 2026.
- ❖ As per our examination on test check basis, the Company has used accounting software (SAP Basics) for maintaining its books of accounts for the financial year ending March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software. Further during the course of audit we didn't come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

For NEERAJ ARORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(Firm's Registration No.: 021309)

NEERAJ Digitally signed
by NEERAJ
KUMAR KUMAR ARORA
Date:
ARORA 2026.05.29
16:06:55 +05'30'

CA Neeraj Arora
(Proprietor)
M. No.: 510750
Place: Gurgaon
Date: May 29, 2026
UDIN: 26510750FJHDAS2671

Neeraj Arora & Associates

B – 20/21, 2nd Floor, Fruit Garden, NIT-5, Faridabad - 121001

www.cwsindia.com



Annexure A – Referred to in paragraph under the heading ‘Report on other Legal and Regulatory Requirements’ of our report of even date to the members of Kimia Biosciences Limited for the year ended March 31, 2026

i. (a) (A) The Company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) The management, during the year, has physically verified the Property, Plant and Equipment of the Company and no material discrepancies were noticed on such physical verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favor of the lessee) disclosed in the financial statements are held in the name of the Company.

(d) As informed and explained to us, the management has not revalued its Property, Plant and Equipment (including right of use assets) or intangible assets or both during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the Company, no proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (previously known as Benami Transactions (Prohibition) Act, 1988) and rules made thereunder.

ii. (a) Physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No discrepancies of 10% or more in the aggregate for each class of inventory were noticed during such physical verification by the management.

(b) As informed and explained to us by the management, the Company has been sanctioned working capital limits in excess of 5 crores rupees, in aggregate, from banks. Details attached below:

Name of Bank	Amount Sanctioned	Date of Sanctioned	Balance as at 31.03.2026
Kotak Mahindra Bank Limited	15.60 Crores	19.02.2026	8.71 Crores
Kotak Mahindra Bank Limited	14.00 Crores	19.02.2026	14.00 Crores

iii. During the year the Company has not provided loans, advances in the nature of loans, stood guarantee or provided security to Companies, Firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii) of the Order are not applicable to the Company.

iv. (a) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not granted any loans, provided any guarantees, or made any investments during the year. Accordingly, reporting under clause 3(iv)(a) is not applicable.

(b) According to the information and explanations given to us, the Company has not provided any guarantees or security in respect of loans, and has not granted any loans to parties covered under Section 185 and 186 of the Companies Act, 2013. Accordingly, reporting under clause 3(iv)(b) is not applicable.

(c) During the first and second quarters of the financial year, the Company has redeemed preference share



capital amounting to Rs. 8,00,00,000.00 in accordance with the terms of issue and the provisions of the Companies Act, 2013.

(d) Based on our examination of the records of the Company and according to the information and explanations given to us, the redemption of preference shares has been duly authorized and is in compliance with the applicable provisions of the Companies Act, 2013. The same has been appropriately accounted for in the books of account and reflected in the capital structure of the Company.

- v. The Company has not accepted any deposits under sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under.
- vi. As per information & explanation given by the management, maintenance of cost records has not been prescribed by the Central Government under sub - section (1) of section 148 of the Act.
- vii. (a) According to the books of accounts and records examined by us, as per the generally accepted auditing practices in India, in our opinion, the Company has been regular in depositing undisputed statutory dues including Goods and Services Tax, Provident Fund, Employee's State Insurance, Income Tax, Duty of Customs, Cess and any other Statutory Dues to the appropriate authorities. According to the information and explanations given to us, there were no undisputed amounts payable in respect of such statutory dues which have remained outstanding as at March 31, 2026 for a period of more than six months from the date they became payable.

(b) According to the information and explanation given to us, there are no amounts payable in respect of Statutory dues which have not been deposited on account of any disputes except the followings:

Name of Statue	Nature of Disputed dues	Amount (Rs. In lakhs)	Period to which it relates	Forum where dispute is pending
Punjab Value Added Tax	Penalty	11.67	2014-15	Panchkula High Court
Income Tax	Section 147	122.40	AY 2019-20	AO
TDS	Penalty	1.51	FY 2007-08, FY 2008-09, FY 2009-10, FY 2012-13, FY 2021-22, FY 2022-23, FY 2023-24, & FY 2025-26	CPC

- viii. According to the explanations and information given to us by the management, there has been no amount surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- ix. (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to lenders.
- (b) According to the information provided to us by the management, the Company has not been declared as a willful defaulter by any bank or financial institution or any other lender.
- (c) The term loans were applied for the purpose for which the loans were obtained.
- (d) On an overall examination of the financial statements of the Company, no funds raised on short term basis have been used for long term purposes by the Company.
- (e) The Company has not taken any funds from any entity or person on account of or to meet the obligations



- xvii. The Company has not incurred any cash losses in the current financial year and immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors during the year.
- xix. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and in our knowledge of the Board of Directors and management plans we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- xx. According to the information and explanations given to us by the management, and on the basis of our examination of the records of the company, there was no such unspent amount to be transferred to the fund specified in schedule VII to the Companies Act, 2013, pursuant to section 135 of the Companies Act, 2013 and therefore sub clauses (a) and (b) of clause (xx) of para 3 are not applicable.
- xxi. Since this report is being issued in respect of standalone financial statements of the company, hence clause (xxi) of paragraph 3 of the said Order is not applicable to the company.

For NEERAJ ARORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(Firm's Registration No.: 021309)

NEERAJ Digitally signed
by NEERAJ
KUMAR KUMAR ARORA
ARORA Date: 2026.05.29
16:07:40 +05'30'

CA Neeraj Arora
(Proprietor)
M. No.: 510750
Place: Gurgaon
Date: May 29, 2026
UDIN: 26510750FJHDAS2671



Annexure B - Referred to in paragraph (f) under the heading 'Report on Other Legal and Regulatory Requirements' of our report of even date to the members of Kimia Biosciences Limited for the year ended March 31, 2026

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of subsection 3 of Section 143 of the Companies Act, 2013 (the "Act")

We have audited the internal financial controls with reference to the financial statements of Kimia Biosciences Limited (the "Company") as of March 31, 2026 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Management of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to the Ind AS financial statements of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by the ICAI and prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to the Ind AS financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to the Ind AS financial statements and their operating effectiveness. Our audit of internal financial controls with reference to the Ind AS financial statements included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to the Ind AS financial statements.

Meaning of Internal Financial Controls with reference to these Ind AS financial statements

A company's internal financial control with reference to these Ind AS financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to these Ind AS financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the



transactions and dispositions of the assets of the company. (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company. and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Ind AS financial statements.

Inherent Limitations of Internal Financial Controls with reference to these Ind AS financial statements

Because of the inherent limitations of internal financial controls with reference to these Ind AS financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Ind AS financial statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these Ind AS financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls over financial reporting with reference to these Ind AS Financial Statements and such internal financial controls over financial reporting with reference to these Ind AS Financial Statements were operating effectively as at March 31, 2026, based on the criteria for internal financial control over financial reporting established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For NEERAJ ARORA & ASSOCIATES

CHARTERED ACCOUNTANTS

(Firm's Registration No.: 021309)

NEERAJ Digitally signed
by NEERAJ
KUMAR KUMAR ARORA
Date: 2026.05.29
ARORA 16:08:18 +05'30'

CA Neeraj Arora

(Proprietor)

M. No.: 510750

Place: Gurgaon

Date: May 29, 2026

UDIN: 26510750FJHDAS2671

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102
 Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com
 Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			FOR THE YEAR ENDED	
		31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	2,719.98	3,010.06	3,824.38	11,488.38	11,892.08
II	Other Income	100.69	9.96	44.20	162.17	132.03
III	Total Income (I+II)	2,820.67	3,020.02	3,868.58	11,650.55	12,024.11
IV	Expenses:					
	a) Cost of materials consumed	1,381.03	1,707.53	2,892.82	6,565.79	7,455.02
	b) Change in inventories of finished goods and work-in-progress	322.26	(60.62)	(449.82)	446.09	(368.23)
	c) Employee benefits expenses	303.87	299.24	278.56	1,261.61	1,367.89
	d) Finance costs	75.30	74.86	140.16	351.57	455.70
	e) Depreciation and amortisation expense	115.51	85.15	87.90	391.32	337.89
	f) Other expenses	446.26	408.43	284.78	1,788.16	1,412.42
V	Total Expenses (IV)	2,644.23	2,514.59	3,234.40	10,804.54	10,660.69
VI	Profit/(loss) before exceptional items and Tax (III-V)	176.44	505.43	634.18	846.01	1,363.42
VII	Exceptional Items	-	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	176.44	505.43	634.18	846.01	1,363.42
VII	Tax expenses:					
	a) Current Tax	-	-	-	-	-
	b) Current Tax related to earlier years	-	-	-	-	-
	b) Deferred Tax charge / (credit)	139.13	(38.72)	435.01	102.64	402.18
VIII	Profit/(loss) for the period (VI-VII)	37.31	544.15	199.17	743.37	961.24
IX	Other Comprehensive Income					
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)					
	- Remeasurement of defined benefit plans	42.85	-	3.04	42.85	3.04
B.	Items that will be reclassified to Profit or Loss (Net of Tax)	(10.78)	-	(0.77)	(10.78)	(0.77)
X	Total Comprehensive Income for the period (VIII+IX)	69.38	544.15	202.98	775.44	963.51
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13
XII	Other Equity					
XIII	Earnings per equity share (not annualised)					
	Basic in Rs.	0.15	1.15	0.43	1.64	2.04
	Diluted in Rs.	0.15	1.15	0.43	1.64	2.04

As per our report of even date attached

FOR KIMIA BIOSCIENCES LIMITED

Neeraj Arora

Partner

Membership No. 510750

NEERAJ KUMAR ARORA Digitally signed by NEERAJ KUMAR ARORA Date: 2026.05.29 16:09:50 +05'30'

Place: Gurgaon
Date: May 29, 2026



Sameer Goel
(Managing Director & CEO)
DIN - 00161786

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102
 Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com
 Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120
 AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026



(₹ Lakhs except EPS)

STATEMENT OF ASSETS, EQUITY and LIABILITIES

S. No.	Particulars	(₹ Lakhs)	
		As at 31-3-2026 (Audited)	As at 31-03-2025 (Audited)
A	ASSETS		
1	Non-Current Assets		
	Property, Plant & Equipment	3,007.70	3,046.06
	Capital Work-in-Progress	16.90	0.32
	Right of Use Assets	14.96	43.82
	Intangible Assets	709.92	237.82
	Financial Assets	-	-
	(i) Other Non Current Financial Assets	44.25	40.88
	Deferred Tax Assets (Net)	62.83	176.25
	Other Non-current Assets	101.14	46.85
2	Current Assets		
	Inventories	2,625.82	3,458.31
	Financial Assets	-	-
	(ii) Trade Receivables	2,932.00	3,675.09
	(iii) Cash and Cash Equivalents	31.58	20.61
	(iv) Bank balances other than (iii) above	50.42	47.49
	(v) Other Current Financial Assets	55.59	105.54
	Current Tax Assets (Net)	75.57	67.94
	Other Current Assets	591.05	154.18
	Total Assets	10,319.73	11,121.16
B	EQUITY & LIABILITIES		
1	EQUITY		
	(a) Share Capital	473.13	473.13
	(b) Other Equity	1,298.92	523.48
2	NON CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	2,280.89	1,037.01
	(ii) Lease Liabilities	4.93	27.59
	(iii) Other financial liabilities	-	632.97
	Provisions	143.49	159.67
	Other Non Current Liabilities	-	84.81
3	CURRENT LIABILITIES		
	Financial Liabilities		
	(i) Borrowings	1,181.90	2,219.62
	(ii) Lease Liabilities	10.81	18.62
	(iii) Trade Payables	-	-
	a. Total Outstanding due to Micro and Small Enterprises	6.18	4.73
	b. Total Outstanding due to other than Micro and Small Enterprises	4,215.27	5,044.16
	(iii) Other Financial Liabilities	295.47	490.56
	Other Current Liabilities	405.58	395.08
	Provisions	3.16	9.73
	Total Equity and Liabilities	10,319.73	11,121.16

As per our report of even date attached

Neeraj Arora

Partner

Membership No. 510750
 NEERAJ Digitally signed by
 KUMAR NEERAJ KUMAR
 ARORA ARORA
 ARORA Date: 2026.05.29
 16:10:12 +05'30'

Place: Gurgaon

Date: May 29, 2026

FOR KIMIA BIOSCIENCES LIMITED



Sameer Gool

Sameer Gool
 (Managing Director & CEO)
 DIN - 00161786

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102
 Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com
 Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026



(₹ Lakhs except EPS)

STATEMENT OF CASH FLOWS		(₹ Lakhs)	
S. No.	Particulars	For the year	For the year
A.	Cash Flow from Operating Activities		
	Net Profit / (Loss) before tax	846.01	1,363.42
	Adjustment for :		
	Depreciation and amortization expense	391.32	337.89
	Finance costs	351.57	455.70
	Gain on fair value of investment in mutual funds	-	-
	Profit on Cancellation of Lease	(3.25)	-
	Interest income	(2.61)	(2.18)
	Deferred revenue income	-	(50.00)
	Unrealised (gain)/loss on foreign currency transactions and translations	(12.26)	(58.94)
	Provision for expected credit loss	-	-
	Provision for doubtful advances	-	-
	Advances written off	-	-
	Operating Profit Before Working Capital Changes	1,570.78	2,045.89
	Adjustments for :		
	(Increase) / Decrease in inventories	832.49	(377.96)
	(Increase)/ Decrease in trade and other receivables	294.40	(1,013.64)
	Increase/ (Decrease) in trade and other payables	(1,575.93)	1,456.35
	Increase/ (Decrease) in Lease Liabilities	(30.47)	15.63
	Cash Generated From Operations	1,091.27	2,126.27
	Less : Income tax paid/ (refunds)	(6.87)	5.17
	Net Cash From Operating Activities	1,084.40	2,131.44
B.	Cash Flow from Investment Activities		
	Purchases of property, plant and equipments including intangible assets & capital advances	(816.13)	(459.92)
	Sale of Investments	-	-
	Net inflow / (outflow) in fixed deposits	(2.93)	(8.81)
	Interest received	10.07	(1.38)
	Net Cash Used In Investing Activities	(808.99)	(470.11)
C.	Cash Flow from Financing Activities		
	Receipts from non current borrowings	540.36	540.36
	Repayment of non current borrowings	703.52	(1,644.33)
	Net proceeds of current borrowings	(1,037.72)	20.47
	Finance costs paid	(470.37)	(571.98)
	Net Cash Used in Financing Activities	(264.21)	(1,655.48)
	Net Increase/(Decrease) in Cash and Cash Equivalents	11.21	5.85
	Cash and Cash Equivalents at the beginning of the period	20.61	14.76
	Cash and Cash Equivalents at the end of the period	31.58	20.61

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for the quarter ended 31st March 2026 and 31st March 2025 are the balancing figures between audited figures for the full financial figures and the published year to date figures for the nine months.
- The Company has carried forward deferred tax assets of Rs. 62.83 Lakhs which in the opinion of the management, based on the future projection the Company is expected to generate taxable income as per business plan and will able to utilize this amount within prescribed period.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 29, 2026.

As per our report of even date attached

Neeraj Arora

Partner

Membership No. 510750

NEERAJ Digitally signed
 KUMAR by NEERAJ
 ARORA KUMAR ARORA
 16:10:31 +05:30

Place: Gurgaon

Date: May 29, 2026

FOR KIMIA BIOSCIENCES LIMITED



Sameer Goel
 (Managing Director & CEO)
 DIN - 00161786

CERTIFICATE PURSUANT TO REGULATION 33(2)(a) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

We, Sameer Goel, Managing Director & CEO and Mani Jain, Chief Financial Officer of the Company hereby certify that the Audited Financial Results (Standalone) for the quarter and year ended March 31, 2026 as placed before the Board of Directors do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading and that the said financial results present a true and fair view of the affairs of the Company.



SAMEER GOEL
(Managing Director & CEO)
DIN- 00161786



MANI JAIN
(Chief Financial Officer)

Date: 29-05-2026

Place: Gurgaon

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel.: +91 11 47063600, 470630601

DECLARATION PURSUANT TO REGULATION 33(3)(d) OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby declare that the Statutory Auditors of the Company, M/s Neeraj Arora & Associates, Chartered Accountants, have issued an Audit Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2026.



SAMEER GOEL
Managing Director & CEO
DIN- 00161786



Date: May 29, 2026
Place: Gurgaon

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel.: +91 11 47063600, 470630601